Program
RSS0343
A development code. Also written as “RSS0343 Tablets”, “RSS0343 Tablet; Rifampicin Capsules” and “RSS0343 Tablet; Clarithromycin Tablets”.
In Jiangsu HengRui Medicine's pipeline, DPP1
. Its studies are mostly in Bronchiectasis · Pulmonary Disease, Chronic Obstructive · Asthma, led by Jiangsu HengRui Medicine.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Jiangsu HengRui Medicine | 43 open or running | phase 2since Jan 9, 2025 | Jan 9, 2025 | Nov 2027phase 2 · NCT06775340 |
- Named in Jiangsu HengRui Medicine’s own pipeline as
RSS0343
, phase 2, as of Jul 31, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jan 9, 2025First study: phase 2 study in Adolescent AsthmaFirst studyNCT06775340 · 252 planned · China
- Dec 4, 2025Phase 1 study in Non-cystic Fibrosis BronchiectasisNCT07289464 · 48 enrolled · China
- Jan 9, 2026Phase 2 study in Pulmonary Disease, Chronic ObstructiveNCT07349524 · 300 planned · China
- Jul 6, 2026Phase 1 study in Non-cystic Fibrosis Bronchiectasis、Chronic Sinusitis Without Nasal Polyps、Chronic Obstructive Pulmonary DiseaseNCT07696091 · 40 planned · China
Ahead
- Nov 2027Primary completion: phase 2 study in Adolescent AsthmaNCT06775340
- Mar 2028Primary completion: phase 2 study in Pulmonary Disease, Chronic ObstructiveNCT07349524
TargetBeta
“DPP1”the company's pipeline, read by Claude · source
Other programs on CTSC
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| verducatib | Boehringer Ingelheim | phase 3 | 21 |
| brensocatibrule | Insmed | phase 3 | 17 |
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07696091Non-cystic Fibrosis Bronchiectasis、Chronic Sinusitis Without Nasal Polyps、Chronic Obstructive Pulmonary Disease · China | 1 | Not yet recruiting | Sep 2026 | 40 |
| NCT07349524Pulmonary Disease, Chronic Obstructive · China | 2 | Recruiting | Mar 2028 | 300 |
| NCT07289464Non-cystic Fibrosis Bronchiectasis · China | 1 | Completed | Aug 10, 2026 | 48 |
| NCT06775340Adolescent Asthma · China | 2 | Recruiting | Nov 2027 | 252 |
How it is read
Names in the registry
- “RSS0343 Tablets”, 1 entry
- “RSS0343 Tablet; Rifampicin Capsules”, 1 entry
- “RSS0343 Tablet; Clarithromycin Tablets”, 1 entry
- “RSS0343 tablets”, 1 entry
- “RSS0343 Tabella”, 1 entry
Codes read as this program: RSS0343.
Conditions, from the studies’ own filings
- Bronchiectasis, 2 studies
- Pulmonary Disease, Chronic Obstructive, 1 study
- Asthma, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.